Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations

Clinical Chemistry

Volumn 54, Issue 6, 2008, Pages 1076-1079

  Shih, Jessie ^a,c   Datwyler, Saul A ^a   Hsu, Stephen C ^a   Matias, Matthew S ^a   Pacenti, David P ^a   Lueders, Christian ^b   Mueller, Christian ^b   Danne, Oliver ^b   Möckel, Martin ^b  

^a ABBOTT DIAGNOSTICS   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CITRIC ACID; EDETIC ACID; HEPARIN; LITHIUM; MYELOPEROXIDASE;

ACCURACY; ACUTE CORONARY SYNDROME; ARTICLE; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EMERGENCY WARD; ENZYME ASSAY; HUMAN; SYMPTOMATOLOGY; TUBE;

ACUTE CORONARY SYNDROME; BLOOD SPECIMEN COLLECTION; HUMANS; PEROXIDASE; TEMPERATURE; TIME FACTORS;

EID: 44849096170     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.101568     Document Type: Article

References (14)

1. Daugherty A, Dunn JL, Rateri D, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437-44.
2. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001;158:879-97.
3. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997;99:2075-81.
4. Brennan M-L, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-604.
5. Baldus S, Heeschen C, Meinertz M, Zeiher AM, Eiserich JP, Munzel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-5.
6. Apple FS, Pearce LA, Chung A, Ler R, Murakami MM. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2007;53:874-81.
7. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, Winterbourn CC. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007;49:1993-2000.
8. Ng LL, Pathik B, Loke IW, Squire IB, Davies JE. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J 2006;152:94-101.
9. Tang WHW, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 2007;49:2364-70.
10. Datwyler SA, Ziemann RN, Shih J. Development of an automated myeloperoxidase (MPO) assay. Clin Chem 2006;52 (6 Suppl):D-11.
11. Datwyler SA, Hsu SC, Matias MA, Pacenti DP, Shih J, Pucci DL. Evaluation of the ARCHITECT myeloperoxidase (MPO) assay in development. Clin Chem Lab Med 2007;45(Supplement):T051.
12. Chang P-Y, Wu T-L, Hung C-C, Tsao K-C, Sun C-F, Wu LL, Wu JT. Development of an ELISA for myeloperoxidase on microplate: normal reference values and effect of temperature on specimen preparation. Clin Chim Acta 2006;373:158-61.
13. Gritters M, Grooteman MPC, Schoorl M, Schoorl M, Bartels PCM, Scheffer PG, et al. Citrate anticoagulation abolished degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during hemodialysis. Nephrol Dial Transplant 2006;21:153-9.
14. Li G, Keenan AC, Young JC, Hall MJ, Pamuklar Z, Ohman EM, et al. Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol 2007;27:1850-6.